Table 1 Patient characteristics, clinical information and tissue oxygenation of the study population (n = 99)

Patient characteristics

 Age (yr)

54.0 ± 7.6

 Sex = male (n (%))

57 (57.6)

 BMI (kg/m2)

22.9 ± 3.4

 NYHA = III (n (%))

66 (66.7)

 Preoperative Cr (umol/L)

86.1 ± 24.3

 LVEF (%)

52.6 ± 5.9

 Euroscore II (%)

1.18 (0.90, 1.75)

 Depth of kidney (cm)

3.3 ± 0.9

Comorbidities

 Atrial fibrillation (n (%))

55 (55.6)

 Pulmonary Hypertension (n (%))

35 (35.4)

 Coronary artery disease (n (%))

9 (9.1)

 Congestive heart failure (n (%))

5 (5.1)

 Stroke (n (%))

6 (6.1)

 Diabetes (n (%))

5 (5.1)

 Hypertension (n (%))

10 (10.1)

 Peptic ulcer disease (n (%))

3 (3.0)

 Dyslipidemia (n (%))

7 (7.1)

 COPD (n (%))

2 (2.0)

 Smoking (n (%))

32 (32.7)

 PCI history (n (%))

4 (4.1)

 PBMV history (n (%))

0 (0)

Current Regular Medication

 Beta-blocker (n (%))

17 (17.2)

 Calcium channel blocker (n (%))

11 (11.1)

 Diuretic (n (%))

91 (91.9)

 Anti-arrhythmic (n (%)

4 (4.0)

 Digoxin (n (%)

34 (34.3)

 Nitroglycerine (n (%)

7 (7.1)

 Statin (n (%))

15 (15.2)

 Inotropic drugs (n (%))

17 (17.2)

 Vasodilator (n (%))

15 (15.2)

 Proton pump inhibitor (n (%))

10 (10.1)

 Low molecular weight heparin (n (%))

4 (4.0)